NOT-DA-20-081: Notice of Change to RFA-OD-20-016, "Emergency Awards: RADx-RAD Multimodal COVID-19 surveillance methods for high risk clustered populations (R01 Clinical Trial Optional)"

Notice of Change to RFA-OD-20-016, "Emergency Awards: RADx-RAD Multimodal COVID-19 surveillance methods for high risk clustered populations (R01 Clinical Trial Optional)"

Notice Number:

NOT-DA-20-081

Key Dates

Release Date:

September 23, 2020

Related Announcements

RFA-OD-20-016 - Emergency Awards: RADx-RAD Multimodal COVID-19 surveillance methods for high risk clustered populations (R01 Clinical Trial Optional)

Issued by

National Institute on Drug Abuse (NIDA)

Purpose

The purpose of this notice is to to inform potential applicants that National Institute on Drug Abuse (NIDA) has made changes, effective immediately, in RFA-OD-20-016, "Emergency Awards: RADx-RAD Multimodal COVID-19 surveillance methods for high risk clustered populations (R01 Clinical Trial Optional).

This Request for Applications has been modified as follows:

In PHS 398 Research Plan,

Removed: “The applicant must acknowledge that they will obtain and retain personal identifiers on all research participants where it is not prohibited (i.e., Tribal data sovereignty) for future longitudinal follow-up and to be leveraged for intervention research”.

In Section V. Application Review Information

Removed: "Grantees are expected to obtain and retain personal identifiers on all research participants where it is not prohibited (i.e., Tribal data sovereignty) for future longitudinal follow-up and to be leveraged for intervention research."

All other aspects of this FOA remain the same.

Inquiries

Please direct all inquiries to:

Please direct all inquiries regarding this Notice to the point(s) of contact listed in the RFA.